In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines
- 270 Downloads
Chemotherapy for advanced well-differentiated carcinoids is characterised by low response rates and short duration of responses. The present study aimed to assess the in vitro activity of novel platinum-based chemotherapeutic drugs in combination with dichloroacetate (DCA), a sensitiser to apoptosis, against lung carcinoid cell lines.
Three permanent cell lines (UMC-11, H727 and H835) were exposed to 14 different established cytotoxic drugs and the novel platinum-based compounds as satraplatin, JM118 and picoplatin in combination with DCA, and viability of the cells was measured using a tetrazoliumbased dye assay.
With exception of the highly chemoresistant UMC-11 line, the carcinoid cell lines (H727, H835) were sensitive to the majority of chemotherapeutics in vitro. Among the platinum-based drugs, carboplatin and oxaliplatin showed highest efficacy. H835 cells growing as multicellular spheroids were 2.7–8.7-fold more resistant to picoplatin, satraplatin and its metabolite compared to single cell suspensions. DCA (10 mM) inhibited the growth of UMC-11 cells by 22% and sensitised these highly resistant cells to carboplatin, satraplatin and JM118 1.4–2.4-fold.
The highly resistant UMC-11 lung carcinoid cells are sensitive to carboplatin, oxaliplatin and the satraplatin metabolite JM118, but multicellular spheroidal growth, as observed in the H835 cell line and pulmonary tumourlets, seems to increase chemoresistance markedly. The activity of carboplatin and JM118 is significantly and specifically increased in combination with the apoptosis sensitiser DCA that promotes mitochondrial respiration over aerobic glycolysis. In summary, among the novel platinum drugs satraplatin has the potential for treatment of lung carcinoids and DCA potentiates the cytotoxicity of selected platinum drugs.
KeywordsCarcinoid Chemosensitivity Drug resistance Platinum complex Picoplatin Satraplatin Dichloroacetate
Unable to display preview. Download preview PDF.
- 8.Plockinger U, Rindi G, Arnold R et al (2004) European Neuroendocrine Tumour Society: guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394–424CrossRefPubMedGoogle Scholar
- 18.Sun W, Lipsitz S, Catalano P et al (2005) Phase II/III Study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897–4904CrossRefPubMedGoogle Scholar
- 24.Dennis MJ, Beijnen JH, Grochow LB, van Warderdam LJC (1997) An overview of the clinical pharmacology of topotecan. Semin Oncol 24:12–18SGoogle Scholar
- 33.Adolphe AB, Glasofer ED, Troetel WM et al (1975) Fate of streptozotocin (NSC-85998) in patients with advanced cancer. Cancer Chemother Rep 9:547–556Google Scholar
- 37.Engstrom PF, Lavin PT, Moertel CG et al (1984) Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 8:865–890Google Scholar
- 54.Otterson GA, Wang L, Wu X et al (2008) Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells. J Clin Oncol 26S:14637Google Scholar